Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR113 in Advanced Solid Tumors
NCT07753590Phase 1Not yet recruiting
- Sponsor
- BioRay Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Feb 2030
01
Overview
Phase 1, open-label, single-arm trial of BR113 in solid tumor (advanced stage), sponsored by BioRay Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 21 days, Treatment-Emergent Adverse Events up to 20 months and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
BR113
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07753590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753590.